Treatment and secondary prevention of venous thromboembolism in cancer patients

Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients.

1. Bokeria L.A., Zatevahin I.I., Kirienko A.I., Andriyashkin A.V., Andriyashkin V.V., Arutiunov G.P. et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiia. 2015;9(4–2):1–52. [Russian: Бокерия Л.А., Затевахин И.И., Кириенко А.И., Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4-2):1-52]

2. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2016;41(1):3–14. DOI: 10.1007/s11239-015-1311-6

3. Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology. 2013;2013(1):684–91. DOI: 10.1182/asheducation-2013.1.684

4. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer: Management of VTE in cancer patients. Journal of Thrombosis and Haemostasis. 2011;9:316–24. DOI: 10.1111/j.1538-7836.2011.04346.x

5. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey. The Oncologist. 2003;8(4):381–8. DOI: 10.1634/theoncologist.8-4-381

6. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al. Prevention of Venous Thromboembolism: The Seventh ACCR Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3):338S-400S. DOI: 10.1378/chest.126.3_suppl.338S

7. Deitcher SR. Cancer-Related Deep Venous Thrombosis: Clinical Importance, Treatment Challenges, and Management Strategies. Seminars in Thrombosis and Hemostasis. 2003;29(3):247–58. DOI: 10.1055/s-2003-40963

8. Trousseau A, Bazire V, Cormack J. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. -London: R. Hardwicke;1867. [Av. at: http://resource.nlm.nih.gov/0224670]

9. Lobastov K.V., Dementieva G.I., Laberko L.A. Current Insights on the Etiology and Pathogenesis of Venous Thrombosis: Virchow’s Triad Revision. Flebologiia. 2019;13(3):227–35. [Russian: Лобастов К.В., Дементьева Г.И., Лаберко Л.А. Современные представления об этиологии и патогенезе венозного тромбоза: переосмысление триады Вирхова. Флебология. 2019;13(3):227-35]. DOI: 10.17116/flebo201913031227

10. Geddings JE, Mackman N. Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873–80. DOI: 10.1182/blood-2013-04-460139

11. Vorobev A.V., Chabrov A.M., Savchenko A.A., Bulgakova S.V., Makatsaria A.D. Pathogenesis of Trousseau’s syndrome. Obstetrics, gynecology and reproduction. 2015;9(2):99–109. [Russian: Воробьев А.В., Чабров А.М., Савченко А.А., Булгакова С.В., Макацария А.Д. Вопросы патогенеза синдрома Труссо. Акушерство, гинекология, репродукция. 2015;9(2):99-109]. DOI: 10.17749/2070-4968.2015.9.2.099-109

12. Clinical cardio-oncology. Herrmann J, editor -Philadelphia, PA: Elsevier;2017. - 491 p. ISBN 978-0-323-44227-5

13. Lipets E.N., Ataullakhanov F.I., Panteleev M.A. Integrated laboratory coagulation tests in hypercoagulation diagnosis and thrombosis risk assessment. Oncohematology. 2015;10(3):73–91. [Russian: Липец Е.Н., Атауллаханов Ф.И., Пантелеев М.А. Интегральные лабораторные тесты гемостаза в диагностике гиперкоагуляции и оценке риска тромбоза. Онкогематология. 2015;10(3):73-91]

14. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, on behalf of the PEGASUS investigators. Randomized clinical trial of postoperative fondaparinuxversus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. British Journal of Surgery. 2005;92(10):1212–20. DOI: 10.1002/bjs.5154

15. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thrombosis Research. 2010;125(Suppl 2):S1–7. DOI: 10.1016/S0049-3848(10)00227-6

16. Lobastov K.V., Barinov V.E., Laberko L.A. Toward the individual approach to the evaluation of risks and prevention of postoperative venous thromboembolism. Flebologiia. 2015;8(1):41–50. [Russian: Лобастов К.В., Баринов В.Е., Лаберко Л.А. На пути к индивидуальному подходу в оценке риска и профилактике послеоперационных венозных тромбоэмболических осложнений. Флебология. 2015;8(1):41-50]. DOI: 10.17116/flebo20159141-50

17. Blom JW, Vanderschoot JPM, Oostindier MJ, Osanto S, Van Der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. Journal of Thrombosis and Haemostasis. 2006;4(3):529–35. DOI: 10.1111/j.1538-7836.2006.01804.x

18. Otten H-MMB, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ et al. Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy: An Underestimated Phenomenon. Archives of Internal Medicine. 2004;164(2):190–4. DOI: 10.1001/archinte.164.2.190

19. Agnelli G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thrombosis Research. 2010;125(Suppl 2):S17–20. DOI: 10.1016/S0049-3848(10)70007-4

20. Blom JW. Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. JAMA. 2005;293(6):715–22. DOI: 10.1001/jama.293.6.715

21. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-e496S. DOI: 10.1378/chest.11-2301

22. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Review of Hematology. 2017;10(1):15–22. DOI: 10.1080/17474086.2017.1257935

23. Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Research and Practice in Thrombosis and Haemostasis. 2017;1(1):14–22. DOI: 10.1002/rth2.12002

24. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 2013;369(9):799–808. DOI: 10.1056/NEJMoa1302507

25. Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. The Lancet Haematology. 2014;1(1):e37–46. DOI: 10.1016/S2352-3026(14)70018-3

26. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). Journal of Clinical Oncology. 2018;36(20):2017–23. DOI: 10.1200/JCO.2018.78.8034

27. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 2019;37:JCO.19.01461. [Epub ahead of print]. DOI: 10.1200/JCO.19.01461

28. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2019;ehz405. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehz405

29. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clinical Pharmacokinetics. 2014;53(1):1–16. DOI: 10.1007/s40262-013-0100-7

30. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis. 2015;114(07):150–7. DOI: 10.1160/TH14-11-0977

31. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. Journal of the National Comprehensive Cancer Network. 2018;16(11):1289–303. DOI: 10.6004/jnccn.2018.0084

32. Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2018;16(9):1891–4. DOI: 10.1111/jth.14219

33. Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients: Multivariable Predictive Model. American Journal of Hematology. 2016;91(10):1014–9. DOI: 10.1002/ajh.24466

34. Abdurakhmanov D.T., Abuzarova G.R., Ageeva T.A., Alekseev S.M., Al-Radi L.S., Aslanidi I.P. et al. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. -M.: The Russian professional society of Oncology & Hematology unit;2018. - 356 p. [Russian: Абдурахманов Д.Т., Абузарова Г.Р., Агеева Т.А., Алексеев С.М., Аль-Ради Л.С., Асланиди И.П. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. – М.:Российское профессиональное общество гематологов, 2018. – 356с]. ISBN 978-5-4465-1990-3

35. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330–93. DOI: 10.1093/eurheartj/ehy136

36. Lee AYY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310–7. DOI: 10.1182/blood-2013-04-460162

37. Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Current Oncology. 2018;25(5):329–37. DOI: 10.3747/co.25.4266